ReviewMolecular and cellular biochemistry2025
Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.
Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence.International journal of molecular sciences · 2025Pooled it
- MuSC cultivation for cultured meat production: recent advances, current limitations, and future directions.Food science of animal resources · 2026Review
- Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.Nature reviews. Neurology · 2026Review
- From Molecular Pathways to Artificial Intelligence: Advancing the Understanding and Management of Osteosarcopenia.International journal of molecular sciences · 2026Review
- Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential.Journal of cardiovascular translational research · 2026Review
- Age-Dependent Effect of Myostatin Blockade in theMuscles (Basel, Switzerland) · 2026Article
- Review
- Pre-Dialysis Serum Myostatin Concentration Is Independently Associated with Intradialytic Muscle Cramps in Hemodialysis Patients.International journal of molecular sciences · 2026Article
- Sarcopenia, cachexia and frailty in older cats: Mechanisms, assessment and therapeutic considerations.Journal of feline medicine and surgery · 2026Review
- Effects of Ferulic Acid on Meat Quality, Carcass Traits, Muscle Fiber Types, and Muscle Development in Shaziling Pigs.Foods (Basel, Switzerland) · 2026Article
- A tri-target in silico analysis of Testolift: a nutraceutical formulation targeting aromatase, myostatin, and prolyl hydroxylase-2 in testosterone regulation and muscle performance.Scientific reports · 2026Article
- Protective effects of irisin in sarcopenia: a promising treatment.Journal of orthopaedic translation · 2026Review
- The role of CXCL10 in high-fat diet-induced skeletal muscle inflammation and atrophy.Journal of diabetes investigation · 2026Article
- Sarcopenia in Chronic Heart Failure: Pathophysiology, Clinical Consequences, and Emerging Multimodal Therapeutic Strategies.Nutrients · 2026Review
- The effects of resistance training on myostatin in older adults with frailty and/or sarcopenia: a systematic review and meta analysis.BMC sports science, medicine & rehabilitation · 2026Article
- Single-cell transcriptomics reveal mechanisms of skeletal muscle differentiation across duck embryonic development.Communications biology · 2026Article
- Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.Diabetes, obesity & metabolism · 2026Review
- Assessing the risk of sarcopenia among community-dwelling older adults in Israel: a national cross-sectional survey.European geriatric medicine · 2026Article
- Serum Growth Differentiation Factor 8 (Myostatin) Concentrations in Cats with Early-Stage Chronic Kidney Disease.Veterinary sciences · 2026Article
- Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myostatin, a potent negative regulator of skeletal muscle mass, has garnered significant attention as a therapeutic target for muscle dystrophies. Despite extensive research and promising preclinical results, clinical trials targeting myostatin inhibition in muscle dystrophies have failed to yield substantial improvements in muscle function or fitness in patients. This review details the mechanisms behind myostatin's function and the various inhibitors that have been tested preclinically and clinically. It also examines the challenges encountered in clinical translation, including issues with drug specificity, differences in serum myostatin concentrations between animal models and humans, and the necessity of neural input for functional improvements. Additionally, we explore promising avenues of research beyond muscle dystrophies, particularly in the treatment of metabolic syndromes and orthopedic disorders. Insights from these alternative applications suggest that myostatin inhibition may hold the potential for addressing a broader range of pathologies, providing new directions for therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.